Stocktoria
SUPERNUS PHARMACEUTICALS, INC. SUPN
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2010-12-28
SUPERNUS PHARMACEUTICALS, INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $719.0M | $661.8M | $607.5M | $667.2M | $579.8M |
| R&D expense | $106.2M | $108.8M | $91.6M | $74.6M | $90.5M |
| SG&A expense | $485.6M | $321.6M | $336.4M | $377.2M | $304.8M |
| Operating income | -$62.3M | $81.7M | -$5.3M | $46.1M | $86.0M |
| Interest expense | — | — | — | — | $19.7M |
| Income tax | -$10.5M | $24.0M | $1.5M | $32,000 | $19.8M |
| Net income | -$38.5M | $73.9M | $1.3M | $60.7M | $53.4M |
| EPS (diluted) | $-0.68 | $1.32 | $0.02 | $1.04 | $0.98 |
| Operating cash flow | $47.3M | $172.0M | $111.1M | $116.8M | $127.1M |
| Free cash flow | $46.0M | $171.2M | $110.5M | $116.4M | — |
| Cash & equivalents | $128.4M | $69.3M | $75.1M | $93.1M | $203.4M |
| Inventory | $112.5M | $54.3M | $77.4M | $91.5M | $86.0M |
| Total assets | $1.5B | $1.4B | $1.3B | $1.7B | $1.7B |
| Total liabilities | $390.9M | $332.3M | $356.2M | $816.3M | $873.3M |
| Shareholders' equity | $1.1B | $1.0B | $921.5M | $886.2M | $815.9M |
Source: SEC EDGAR filings · CIK 0001356576 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.